Venture capitalists buy into TROP2
Blackstone follows Abingworth, but why?
A cautionary tale for clinical trial collaborators
AstraZeneca ended a tie-up with Asher, and then set off on its own.
Bispecific cytokine delivers for Innovent at last
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Ipsen sees a future in gammadelta T-cells
The company will acquire ImCheck for €350m.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
